Dear EURETINA Members, A very warm welcome to the August 23rd, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 23rd, 2024 “EURETINA-Brief”© Issue No. 298
Researchers at the Department of Ophthalmology, Boston Children’s Hospital, and the Harvard Medical School, have reported that the interface of photoreceptors and RPE in Stargardt… Read More »Analysis of data from AO-SLO images on Stargardt disease patients show clear profiles of hyper-reflective bands, potentially targeted for pharmaceutical treatment.
An international consortium of researchers on a multi-centre study on congenital stationary night blindness (CSNB), led by Oregon Health and Science University Casey Eye Institute,… Read More »An international multi-centre study on congenital stationary night blindness (CSNB) report several genetic variants on myopia.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced interim 24-week data from their “PRISM” (WET AMD) and “SPECTRA” (DME) phase I/II… Read More »Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.
Dear EURETINA Members, A very warm welcome to the August 8th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »August 8th, 2024 “EURETINA-Brief”© Issue No. 297
In a recent study published in the prestigious journal Nature Communications (2024 Jul 21;15[1]:6150), researchers have reported that an upstream regulator, “AKT2” (a member of… Read More »Researchers identify that lysosomal biogenesis and mitochondrial signalling may suggest new therapeutic targets for dry-AMD.
Researchers at Janssen Pharmaceuticals N.V. and the ERN-EYE Network at the Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, Padua, Italy, have reported results… Read More »Results from a cross sectional study of XLRP patients suggest that several healthcare systems require early diagnosis and effective management of patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) have announced the receipt of Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of IRDs, including… Read More »Kioro Pharmaceuticals (NASDAQ: KPRX) has announced Orphan Medicinal Product Designation for KIO-310, for the treatment of non-syndromic rod-dominant retinal dystrophies.
Dear EURETINA Members, A very warm welcome to the July 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 24th, 2024 “EURETINA-Brief”© Issue No. 296
Researchers at the School of Pharmacy, University of Eastern Finland, and the Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology, University of… Read More »Re-purposed drugs for retinitis pigmentosa may address mutation-independent approach for retinal degenerations.
